DIREKT: Disarming the intravascular innate immune response to improve modalities for chronic kidney disease treatment

点击翻译按钮获取中文摘要

Dialysis is the mainstay treatment for patients with end-stage kidney disease while they await transplantation. However, the dialysis process causes inflammation in patients, affecting their health and longevity. This project aims to develop new bioreagents that can be applied to dialysis devices to reduce inflammation and thus improve patient outcomes. These bioreagents will also be used to modify donor kidneys so that they are protected from inflammation associated with transplantation.